508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
Keyword(s):
Phase Ii
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. TPS189-TPS189
2014 ◽
Vol 32
(15_suppl)
◽
pp. TPS3649-TPS3649
◽